Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination

References

• 2011 National Diabetes Fact Sheet [webpage on the Internet]Atlanta, GACenters for Disease Control and Prevention2013 Available from: http://www.cdc.gov/diabetes/pubs/factsheet11.htmAccessed August 27, 2013
   Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2013Diabetes Care201336Suppl 1S11S6623264422
   PubMed Web of Science ®Google Scholar
• [No authors listed]Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• [No authors listed]The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research GroupN Engl J Med1993329149779868366922
   PubMed Web of Science ®Google Scholar
• HolmanRRPaulSKBethelMAMatthewsDRNeilHA10-year follow-up of intensive glucose control in type 2 diabetesN Engl J Med2008359151577158918784090
   PubMed Web of Science ®Google Scholar
• IDF Diabetes Atlas Update 2012 [webpage on the Internet]BrusselsInternational Diabetes Federation2012 Available from: http://www.idf.org/diabetesatlas/5e/Update2012Accessed August 27, 2013
   Google Scholar
• InzucchiSEOral antihyperglycemic therapy for type 2 diabetes: scientific reviewJAMA2002287336037211790216
   PubMed Web of Science ®Google Scholar
• FoxKMGerber PharmdRABolinderBChenJKumarSPrevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002Clin Ther200628338839516750453
   PubMed Web of Science ®Google Scholar
• BarnettAHRedefining the role of thiazolidinediones in the management of type 2 diabetesVasc Health Risk Manag20095114115119436665
   PubMedGoogle Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA)European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• RodbardHWJellingerPSDavidsonJAStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract200915654055919858063
   PubMed Web of Science ®Google Scholar
• BlackburnDFSwidrovichJLemstraMNon-adherence in type 2 diabetes: practical considerations for interpreting the literaturePatient Prefer Adherence2013718318923487395
   PubMed Web of Science ®Google Scholar
• CramerJAA systematic review of adherence with medications for diabetesDiabetes Care20042751218122415111553
   PubMed Web of Science ®Google Scholar
• AscheCLaFleurJConnerCA review of diabetes treatment adherence and the association with clinical and economic outcomesClin Ther20113317410921397776
   PubMed Web of Science ®Google Scholar
• KoliakiCDoupisJLinagliptin/metformin fixed-dose combination treatment: a dual attack to type 2 diabetes pathophysiologyAdv Ther20122912993100423184570
   PubMed Web of Science ®Google Scholar
• Oral Diabetes Medications Summary Chart [webpage on the Internet]Boston, MAJoslin Diabetes Center2013 Available from: http://www.joslin.org/info/oral_diabetes_medications_summary_chart.htmlAccessed August 27, 2013
   Google Scholar
• BrazgRXuLDalla ManCCobelliCThomasKSteinPPEffect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetesDiabetes Obes Metab20079218619317300594
   PubMed Web of Science ®Google Scholar
• BosiEDottaFJiaYGoodmanMVildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitusDiabetes Obes Metab200911550651519320662
   PubMed Web of Science ®Google Scholar
• PatlakMNew weapons to combat an ancient disease: treating diabetesFASEB J200216141853
   Web of Science ®Google Scholar
• ProksPReimannFGreenNGribbleFAshcroftFSulfonylurea stimulation of insulin secretionDiabetes200251Suppl 3S368S37612475777
   PubMed Web of Science ®Google Scholar
• CruzanSMFDA approves new diabetes drug [press release]1994 [December 30]. Available from: http://web.archive.org/web/20070929152824/http://www.fda.gov/bbs/topics/ANSWERS/ANS00627.htmlAccessed July 26, 2013
   Google Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care20062981963197216873813
   PubMed Web of Science ®Google Scholar
• Van de LaarFALucassenPLAkkermansRPVan de LisdonkEHRuttenGEVan WeelCAlpha-glucosidase inhibitors for type 2 diabetes mellitusCochrane Database Syst Rev20052CD00363915846673
   PubMed Web of Science ®Google Scholar
• LamannaCMonamiMMarchionniNMannucciEEffect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trialsDiabetes Obes Metab201113322122821205121
   PubMed Web of Science ®Google Scholar
• IdrisIWarrenGDonnellyRAssociation between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetesArch Intern Med2012172131005101122688528
   PubMedGoogle Scholar
• NissenSEWolskiKRosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortalityArch Intern Med2010170141191120120656674
   PubMed Web of Science ®Google Scholar
• LewisJDFerraraAPengTRisk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort studyDiabetes Care201134491692221447663
   PubMed Web of Science ®Google Scholar
• Symlin [webpage on the Internet]Drugs.com2013 [revised December 3, 2010]. Available from: http://www.drugs.com/symlin.htmlAccessed August 27, 2013
   Google Scholar
• KleppingerELVivianEMPramlintide for the treatment of diabetes mellitusAnn Pharmacother2003377–81082108912841822
   PubMed Web of Science ®Google Scholar
• HollanderPALevyPFinemanMSPramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trialDiabetes Care200326378479012610038
   PubMed Web of Science ®Google Scholar
• JonesMCTherapies for diabetes: pramlintide and exenatideAm Fam Physician200775121831183517619527
   PubMed Web of Science ®Google Scholar
• FerranniniERamosSJSalsaliATangWListJFDapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trialDiabetes Care201033102217222420566676
   PubMed Web of Science ®Google Scholar
• AbrahamsonMJPetersAIntensification of insulin therapy in patients with type 2 diabetes mellitus: an algorithm for basal-bolus therapyAnn Med201244883684622822902
   PubMed Web of Science ®Google Scholar
• CampbellRKRecommendations for improving adherence to type 2 diabetes mellitus therapy – focus on optimizing insulin-based therapyAm J Manag Care201218Suppl 3S55S6122558943
   PubMedGoogle Scholar
• JonassenIHavelundSHoeg-JensenTSteensgaardDBWahlundPORibelUDesign of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulinPharm Res20122982104211422485010
   PubMed Web of Science ®Google Scholar
• BergenstalRMRosenstockJArakakiRFA randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetesDiabetes Care201235112140214722787177
   PubMed Web of Science ®Google Scholar
• PoriesWJSwansonMSMacDonaldKGWho would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitusAnn Surg19952223339350 discussion 350–3327677463
   PubMed Web of Science ®Google Scholar
• BuchwaldHEstokRFahrbachKWeight and type 2 diabetes after bariatric surgery: systematic review and meta-analysisAm J Med20091223248256. e24519272486
   PubMed Web of Science ®Google Scholar
• CaoYLiYKimJOrally efficacious novel small molecule 6-chloro-6-deoxy-1,2,3,4-tetra-O-galloyl-alpha-D-glucopyranose selectively and potently stimulates insulin receptor and alleviates diabetesJ Mol Endocrinol2013511152623549408
   PubMed Web of Science ®Google Scholar
• GanugapatiJBaldwaALalaniSMolecular docking studies of banana flower flavonoids as insulin receptor tyrosine kinase activators as a cure for diabetes mellitusBioinformation20128521622022493522
   PubMedGoogle Scholar
• ElrickHStimmlerLHladCJJrAraiYPlasma insulin response to oral and intravenous glucose administrationJ Clin Endocrinol Metab1964241076108214228531
   PubMed Web of Science ®Google Scholar
• NauckMAHombergerESiegelEGIncretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responsesJ Clin Endocrinol Metab19866324924983522621
   PubMed Web of Science ®Google Scholar
• KumarASecond line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitorsDiabetes Metab Res Rev201228Suppl 2212523280862
   PubMed Web of Science ®Google Scholar
• PetersAIncretin-based therapies: review of current clinical trial dataAm J Med2010123Suppl 3S28S3720206729
   PubMed Web of Science ®Google Scholar
• DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet 112006368954816961705
   PubMed Web of Science ®Google Scholar
• MentisNVardarliIKötheLDGIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetesDiabetes20116041270127621330636
   PubMed Web of Science ®Google Scholar
• WyshamCHBlevinsTCArakakiREfficacy and safety of dulaglutide vs placebo and exenatide in type 2 diabetes (AWARD-1). Efficacy and safety of dulaglutide vs placebo and exenatide in type 2 diabetes (AWARD-1). Abstract 66-ORPresented at: American Diabetes Association (ADA) 73rd Scientifc SessionsJune 21–25, 2013Chicago, IL
   Google Scholar
• Europe approval status for Albiglutide: [webpage on the Internet] Available from http://www.gsk.com/media/press-releases/2013/regulatory-update--gsk-announces-regulatory-submission-for-albig.htmlAccessed December 17, 2013
   Google Scholar
• US approval status for Albiglutide : [webpage on the Internet] Available from http://google2.fda.gov/searchq=Albiglutide&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&output=xml_no_dtd&getfields=Accessed December 17, 2013
   Google Scholar
• LovshinJADruckerDJIncretin-based therapies for type 2 diabetes mellitusNat Rev Endocrinol20095526226919444259
   PubMed Web of Science ®Google Scholar
• MartinJHDeaconCFGorrellMDPrinsJBIncretin-based therapies – review of the physiology, pharmacology and emerging clinical experienceIntern Med J201141429930721299778
   PubMed Web of Science ®Google Scholar
• Victoza (liraglutide [rDNA origin]) injection: Rems – risk of thyroid C-cell tumors, acute pancreatitis [wepage on the Internet]Silver Spring, MDUS Food and Drug Administration2011 [updated June 13, 2011]. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258826.htmAccessed August 27, 2013
   Google Scholar
• PhenomixSafety and Efficacy study of dutogliptin/PHX1149T to treat type 2 diabetes mellitus Availabe from http://clinicaltrials.gov/ct2/show/NCT00690638?term=Dutogliptin&rank=9. Identifier NCT00690638
   Google Scholar
• NathanDMBuseJBDavidsonMBAmerican Diabetes AssociationEuropean Association for Study of DiabetesMedical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care200932119320318945920
   PubMed Web of Science ®Google Scholar
• MazzolaNReview of current and emerging therapies in type 2 diabetes mellitusAm J Manag Care201218Suppl 1S17S2622559854
   PubMedGoogle Scholar
• Onglyza™ (Saxagliptin), a New Treatment for Type 2 Diabetes Mellitus in Adults, Now Available in US Pharmacies [press release]Bristol-Myers Squibb Company; AstraZeneca2009 [August 14]. Available from: http://www.bms.com/Documents/news/onglyza_available.pdfAccessed July 29, 2013
   Google Scholar
• CHMP Assessment Report for OnglyzaLondonEuropean Medicines Agency2009 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001039/WC500044319.pdfAccessed July 29, 2013
   Google Scholar
• Onglyza FAQs [webpage on the Internet]Bristol-Myers Squibb Company; AstraZeneca Pharmaceuticals LP2013 Available from: http://www.onglyza.com/about/faq.aspxAccessed July 29, 2013
   Google Scholar
• Onglyza (saxagliptin) tablets [prescribing information]Princeton, NJBristol-Myers Squibb Company Wilmington, DE: AstraZeneca Pharmaceuticals LP2013 Available from: http://packageinserts.bms.com/pi/pi_onglyza.pdfAccessed July 29, 2013
   Google Scholar
• 74 studies found for: saxagliptin [webpage on the Internet]ClinicalTrials.gov2013 Available from: http://clinicaltrials.gov/ct2/results?term=saxagliptin&Search=SearchAccessed July 29, 2013
   Google Scholar
• DickersinKSchererRLefebvreCIdentifying relevant studies for systematic reviewsBMJ19943096964128612917718048
   PubMed Web of Science ®Google Scholar
• HoPMRumsfeldJSMasoudiFAEffect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitusArch Intern Med2006166171836184117000939
   PubMed Web of Science ®Google Scholar
• Adherence to long-term therapies: evidence for action [webpage on the Internet]GenevaWorld Health Organization2013 Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/Accessed July 27, 2013
   Google Scholar
• MelikianCWhiteTJVanderplasADeziiCMChangEAdherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapyClin Ther200224346046711952029
   PubMed Web of Science ®Google Scholar
• HermansMPDelibasiTFarmerIEffects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT studyCurr Med Res Opin201228101635164523020253
   PubMed Web of Science ®Google Scholar
• UpretiVVKeungCFBoultonDWBioequivalence of saxagliptin/metformin immediate release (IR) fixed-dose combination tablets and single-component saxagliptin and metformin IR tablets in healthy adult subjectsClin Drug Investig2013335365374
   PubMed Web of Science ®Google Scholar
• BoultonDWSmithCHLiLHuangJTangALaCretaFPBioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjectsClin Drug Investig2011319619630
   PubMed Web of Science ®Google Scholar
• DeFronzoRAHissaMNGarberAJSaxagliptin 014 Study GroupThe efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin aloneDiabetes Care20093291649165519478198
   PubMed Web of Science ®Google Scholar
• LiuYHongTCombination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidenceDiabetes Obes Metab Epub5132013
   Web of Science ®Google Scholar
• ChacraARTanGHRavichandranSListJChenRCV181040 InvestigatorsSafety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeksDiab Vasc Dis Res20118215015921562067
   PubMed Web of Science ®Google Scholar
• FassADGershmanJAEfficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metforminAdv Ther201330433735323605247
   PubMed Web of Science ®Google Scholar
• CookWBryzinskiBSlaterJFrederichRAllenESaxagliptin efficacy and safety in patients with type 2 diabetes mellitus and cardiovascular disease history or cardiovascular risk factors: results of a pooled analysis of phase 3 clinical trialsPostgrad Med2013125314515423748515
   PubMed Web of Science ®Google Scholar
• GersteinHCMillerMEByingtonRPEffects of intensive glucose lowering in type 2 diabetesN Engl J Med2008358242545255918539917
   PubMed Web of Science ®Google Scholar
• SciricaBMBhattDLBraunwaldEThe design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 studyAm Heart J20111625818825. e622093196
   PubMed Web of Science ®Google Scholar
• AstraZeneca and Bristol-Myers Squibb announce top line results for SAVOR-TIMI-53 cardiovascular outcomes trial of Onglyza® (saxagliptin) [press release]Princeton, NJBristol-Myers Squibb Wilmington, DE: AstraZeneca; 2013 [June 19]. Available from: http://news.bms.com/press-release/astrazeneca-and-bristol-myers-squibb-announce-top-line-results-savor-timi-53-cardiovasAccessed July 29, 2013
   Google Scholar
• KaryekarCSRavichandranSAllenEFlemingDFrederichRTolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥65 years) with inadequately controlled type 2 diabetes mellitusClin Interv Aging2013841943023626461
   PubMed Web of Science ®Google Scholar
• JerumsGPanagiotopoulosSPremaratneEMacIsaacRJIntegrating albuminuria and GFR in the assessment of diabetic nephropathyNat Rev Nephrol20095739740619556994
   PubMed Web of Science ®Google Scholar
• LipskaKJBaileyCJInzucchiSEUse of metformin in the setting of mild-to-moderate renal insufficiencyDiabetes Care20113461431143721617112
   PubMed Web of Science ®Google Scholar
• ZanchiALehmannRPhilippeJAntidiabetic drugs and kidney disease – recommendations of the Swiss Society for Endocrinology and DiabetologySwiss Med Wkly2012142w1362922987488
   PubMed Web of Science ®Google Scholar
• NowickiMRychlikIHallerHLong-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety studyInt J Clin Pract201165121230123921977965
   PubMed Web of Science ®Google Scholar
• CornellSAA patient-centred approach to treatment with incretin-based agents in patients with type 2 diabetesJ Clin Pharm Ther201338318118923442106
   PubMed Web of Science ®Google Scholar
• PeyrotMRubinRRLauritzenTSnoekFJMatthewsDRSkovlundSEPsychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) StudyDiabet Med200522101379138516176200
   PubMed Web of Science ®Google Scholar
• CornellSDifferentiating among incretin therapies: a multiple-target approach to type 2 diabetesJ Clin Pharm Ther201237551052422436069
   PubMed Web of Science ®Google Scholar
• NauDPRecommendations for improving adherence to type 2 diabetes mellitus therapy – focus on optimizing oral and non-insulin therapiesAm J Manag Care201218Suppl 3S49S5422558942
   PubMedGoogle Scholar
• GokeBGallwitzBErikssonJHellqvistAGause-NilssonISaxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trialInt J Clin Pract201064121619163120846286
   PubMed Web of Science ®Google Scholar
• NadeauDAPartnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetesPostgrad Med2010122371520463409
   PubMed Web of Science ®Google Scholar
• JendleJTorffvitORidderstraleMLammertMEricssonABogelundMWillingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetesCurr Med Res Opin201026491792320163195
   PubMed Web of Science ®Google Scholar
• ErhardtWBergenheimKDuprat-LomonIMcEwanPCost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysisClin Drug Investig2012323189202
   PubMed Web of Science ®Google Scholar
• HansenRAFarleyJFDroegeMMaciejewskiMLA retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005Clin Ther20103271308131920678679
   PubMed Web of Science ®Google Scholar
• ElgartJFCaporaleJEGonzalezLAielloEWaschbuschMGagliardinoJJTreatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in ArgentinaHealth Econ Rev2013311123621944
   PubMedGoogle Scholar
• NitaMEEliaschewitzFGRibeiroECost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the treatment of diabetes mellitus type 2 in the Brazilian private health systemRev Assoc Med Bras201258329430122735220
   PubMed Web of Science ®Google Scholar
• Aphorisms [webpage on the Internet] Available from: http://classics.mit.edu/Hippocrates/aphorisms.1.i.htmlAccessed July 27, 2013
   Google Scholar
• MontoriVMGafniACharlesCA shared treatment decision-making approach between patients with chronic conditions and their clinicians: the case of diabetesHealth Expect200691253616436159
   PubMed Web of Science ®Google Scholar
• PorzsoltFClouthJDeutschmannMHipplerHJPreferences of diabetes patients and physicians: a feasibility study to identify the key indicators for appraisal of health care valuesHealth Qual Life Outcomes2010812521050469
   PubMed Web of Science ®Google Scholar
• Drugs.com [homepage on the Internet]Drugs.com2013 Available from: http://www.drugs.comAccessed July 21, 2013
   Google Scholar
• FrederichRMcNeillRBerglindNFlemingDChenRThe efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment- naïve patients with type 2 diabetes mellitus: a randomized controlled trialDiabetol Metab Syndr2012413622828124
   PubMed Web of Science ®Google Scholar
• DaveDJSaxagliptin: a dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitusJ Pharmacol Pharmacother20112423023522025849
   PubMedGoogle Scholar